Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
So who else could be interested in the oestrogen degrader?
